OLIGOFASTX aims to combine resources and efforts to create a platform that facilitates and contributes to the generation in Spain of a biopharmaceutical industrial fabric specialised in the development of oligonucleotide-based therapies with RNA as a common thread.

The project seeks long-term collaboration based on complementarity between companies and specialised research centres, covering the entire development cycle of these drugs.


OLIGOFASTX has the ultimate goal of pooling resources and efforts to create a comprehensive platform to facilitate and contribute to the accelerated development of RNA oligonucleotide-based therapies (ASOs, siRNAs and aptamers) in Spain.

The seven constituent entities are specialised in the different activities necessary to complete the oligonucleotide-based drug development cycle, creating the industrial fabric necessary for the emergence of new RNA-based therapies.


  • The development of a comprehensive platform for new therapies based on three oligonucleotide-based technologies, Antagomirs, siRNAs and Aptamers, that will drive and facilitate the arrival on the market of new therapies for the treatment of rare diseases with no medical response;
  • The constitution of an integrated system of activities and processes through collaboration between entities that will enable the design, synthesis, release and development of RNA-based drugs. This system will make it possible to address the treatment of any disease – both rare and high-incidence – although the framework of the CDTI-funded project is limited to developments for rare diseases.
Read more

OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) with the participation of six other Spanish companies.

Design, modeling and AI

Nanotechnology and drug delivery


and escaling


Celebrating World Health Day: “My health, my right”

At OLIGOFASTX, we work to develop therapeutic solutions for patients living with rare diseases. That [...]

Approval, registration and marketing of therapeutic oligos

In this eighth and final instalment of our #DiscoveringOligonucleotides series, we delve into the process [...]

Exploring the new frontiers of biotechnology

Biotechnology has expanded our understanding and ability to address human health challenges. However, the path [...]

Clinical trials: a journey towards hope in rare diseases

Clinical trials have been a fundamental pillar in the advancement of medicine and pharmaceutical research. [...]

#8M Commemorating International Women’s Day: inspiring voices from OLIGOFASTX

On International Women’s Day, we join the world in celebrating the achievements and continuing struggle [...]

World Rare Disease Day: embracing the rarity of a leap year

In a leap year like the current one, where 29 February takes on a special [...]

#DiscoveringOligonucleotides: exploring the synthesis and scale-up of therapeutic oligonucleotides

In this sixth installment of our #DiscoveringOligonucleotides series, we delve into the synthesis and scale-up [...]

Oligonucleotide biosynthesis: driving precision medicine towards a sustainable future

Precision medicine has seen extraordinary advances in recent years, driven largely by research into oligonucleotide [...]

Preclinical development of therapeutic oligonucleotides

In the fifth installment of our #DiscoveringOligonucleotides series, we dive into the preclinical development phase. [...]

2023: a key year for therapeutic oligos

Since the pioneering approval of Fomivirsen in 1998, the field of oligonucleotides has undergone a [...]

Therapeutic oligonucleotide delivery systems

In this fourth installment of our #DiscoveringOligonucleotides series, we explore a crucial challenge for innovative [...]

OLIGOFASTX Milestones 2023

We are coming to the end of this year and through this post we want [...]

Design of therapeutic oligonucleotides

Therapeutic oligonucleotides represent a breakthrough technology in genetic medicine, specifically addressing diseases at the molecular [...]

Orphan drugs not to forget anyone

In the field of medicine, orphan drugs have stood out as silent heroes, bringing hope [...]

RNA therapies and their transformative impact on precision medicine

In this second issue of #DiscoveringOligonucleotides, from the OLIGOFASTX consortium we want to introduce you [...]

Science and Innovation Week: an opportunity to get closer to the world of science

Science Week is a unique opportunity to get closer to the fascinating world of science. [...]

Challenges and ethics in the integration of Artificial Intelligence in the pharmaceutical industry

At the intersection of technological innovation and healthcare, artificial intelligence (AI) is emerging as a [...]

Introduction to Therapeutic Oligonucleotides: Transforming Medicine from Genetics

Therapeutic oligonucleotides have emerged as an exciting and promising class of drugs capable of offering [...]

Fire and Mello’s discovery of siRNAs: master keys to fighting disease

Small interfering RNA molecules (commonly known by the acronym siRNA small interfering RNA) represent one [...]

The transformation of drug delivery in modern medicine

From the 1980s and 1990s to the present day, the field of drug delivery has [...]

Larry Gold and Craig Tuerk: Pioneers in the Discovery of Aptamers

Advances in science and technology are often the result of the dedication, passion and collaboration [...]

The Annual Celebration of Scientific Excellence: The Nobel Prizes

Each year, the world of science and research unites in a celebration of excellence, innovation [...]

BioSpain 2023: record attendance, conferences and with RNA and precision medicine as the protagonist

Last week, several representatives of the OLIGOFASTX consortium partners attended BioSpain 2023, which has been [...]

European Biotechnology Week: latest developments in the sector

The European Biotech Week 2023 (European Biotech Week #EBW2023) with various events in the different [...]

David Bartel and microRNAs

David Bartel (Birmingham, 1958) is a leading researcher in molecular and cell biology who has [...]

Next most relevant congresses in the biotechnology sector

The biotechnology industry continues to grow and evolve, a good proof of this is the [...]

The wide range of job opportunities in the biopharmaceutical sector

The pharmaceutical industry is a constantly growing sector that plays a fundamental role in the [...]

The authorization process of a drug in Spain: phases and requirements

At OLIGOFASTX we are working to achieve solutions that improve the quality of life of [...]

The evolution of knowledge about RNA: from its discovery to the present day

RNA is an essential molecule for life, but its discovery and understanding has been a [...]

10 Practical Tips for Parents of Children Affected by Rare Diseases

In this article, practical advice for parents of children affected by rare diseases will be [...]

RNA Bibliography: a selection of the most influential publications in the field of biotechnology

RNA Bibliography: a selection of the most influential publications in the field of biotechnology In [...]

Innovation on the horizon: how big pharma investment is driving the development of oligonucleotide-based medicines

The mission of the OLIGOFATSX project is to develop oligonucleotide-based medicines to improve the quality [...]

Enzymes: key molecules for the development of oligonucleotides

The OLIGOFASTX team is focused on the development of oligonucleotide-based therapies for certain rare diseases [...]

From research to the public: the importance of clear and accessible science communication

Clear and accessible science communication is essential to bring research advances closer to the general [...]

Nanotechnology: a key tool for developing new drugs

Nanotechnology is a field that has revolutionised the pharmaceutical industry. The ability to manipulate materials [...]

Hope for patients with Fuchs’ Endothelial Corneal Dystrophy: Innovations in treatment

Today we talk in our blog about another of the rare diseases that the OLIGOFASTX [...]

The fight against cancer: past, present and future

The European Week Against Cancer 2023 will be held from May 25 to 31 with [...]

A day to recognize the role of clinical research: International Clinical Trials Day

May 20 marks International Clinical Trials Day, a date designed to highlight the importance of [...]

Computational Modeling in the service of health

Technological evolution is increasingly present in all areas of our lives. In today’s article we [...]

The experiment that helped crack the code of life

In 1961, Marshall Nirenberg and Heinrich Matthaei discovered the genetic code of living beings, which [...]

April 18th: European Patients’ Rights Day

Today, the OLIGOFASTX team joins in the celebration of the European Patients’ Rights Day, a [...]

Alström syndrome: a rare disease with many comorbidities and complications

Rare diseases (affecting fewer than 1 in 2,000 people) are an emerging global public health [...]

Artificial Intelligence applied to the diagnosis and treatment of rare diseases

That Artificial Intelligence is coming to our daily lives is nothing new. We have all [...]

Tribute to Severo Ochoa, the Spanish biochemist who received the Nobel Prize for discovering the enzymes involved in RNA synthesis.

Of Spanish origin, the small and idyllic town of Luarca (Asturias) was the birthplace of [...]

Spanish pharmaceutical industry, third largest exporter with 53% growth to 2022

We love to share good news from the sector. On this occasion, we share the [...]

#8M, #InternationalWomensDay: “For an inclusive digital world”

One more year, we celebrate #InternationalWomensDay: a day that not only commemorates and pays tribute [...]

Rare Disease Day

Oligofastx is a project born from a need: to offer a therapeutic pathway based on [...]

Metaverse opens new opportunities for research and collaboration

If there is one word that distinguishes OLIGOFASTX and its philosophy, it is innovation. Thanks [...]

The contribution of women in science

Since 2015, the International Day of Women and Girls in Science has been celebrated every [...]

World Cancer Day

As it could not be otherwise, from Oligofastx we join in the celebration of the [...]

Leber Congenital Amaurosis

Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner [...]

A 2023 with a hopeful look at therapeutic oligonucleotides

The last few years have been a true revolution in terms of discoveries and initiatives [...]

Cancer cachexia

Cancer cachexia is a complex metabolic syndrome characterized by marked loss of body weight, anorexia, [...]

Providing solutions for rare diseases: a priority for the UN

Perhaps the definition is not the most accurate, but in reality a rare disease does [...]

Goodbye 2022, welcome 2023

In the last days of the year, it is time to review everything we have [...]

Innovative and sustainable production of biological molecules

The Oligofastx project covers all areas, from start to finish, of the process of developing [...]

Personalized treatments for rare diseases with oligonucleotides pose universal challenges

There is no doubt that oligonucleotide therapies aimed at providing answers and improving the quality [...]

Oligonucleotides, the language of life in small doses

A technological revolution can start with a key concept, the application of an equation or, [...]

Solid-phase synthesis in the amplification and sequencing of nucleic acids

The Oligofastx project covers the different phases of the development of oligonucleotide-based therapies, from design [...]

Oligonucleotides for curing osteoporosis, premature aging in children and hepatitis B

OLIGOFASTX follows with great interest all the recent advances in the work with oligonucleotides, not [...]

Maurice Wilkins, the third man of the double helix

History is peppered with stories, legends and tales. And as in all of them, any [...]

Anaplastic thyroid cancer: the most aggressive and lethal type of cancer

Thyroid cancer is a common malignancy of the endocrine system. There are four types: Papillary [...]

Guillain-Barré Syndrome: when the immune system attacks peripheral nerves

Today we are going to talk about one of those diseases classified as rare, for [...]

The Most Excellent Nobel Laureates 2022: these were the winners in the categories of Chemistry and Medicine

The work of the most renowned scientists, artists and diplomats is rewarded every year at [...]

Retinitis pigmentosa, a genetic vision pathology

Every last Sunday of September is celebrated the International Retinitis Pigmentosa Day, one of the [...]

Steinert’s myotonic dystrophy: when muscles become unresponsive

Today is International Myotonic Dystrophy Day, a rare disease with no treatment or cure to [...]

The OLIGOFASTX project is born

The project, subsidised by the CDTI with 5.4 million euros and a final budget of [...]